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Myeloid cell interactions with cells of the adaptive immune system are an essential aspect
of immunity. A key aspect of that interrelationship is its modulation by the
microenvironment. Oxygen is known to influence myelosuppression of T cell activation
in part via the Hypoxia inducible (HIF) transcription factors. A number of drugs that act on
the HIF pathway are currently in clinical use and it is important to evaluate how they act on
immune cell function as part of a better understanding of how they will influence patient
outcomes. We show here that increased activation of the HIF pathway, either through
deletion of the negative regulator of HIF, the von Hippel-Lindau (VHL) gene, in myeloid
cells, or through pharmacological inhibitors of VHL-mediated degradation of HIF, potently
suppresses T cell proliferation in myeloid cell/T cell culture. These data demonstrate that
both pharmacological and genetic activation of HIF in myeloid cells can suppress adaptive
cell immune response.
Keywords: Nitric oxide, hypoxia, immunosuppression, HIF, myeloid cells, von Hippel-Lindau., Prolyl
hydroxylase inhibitorsINTRODUCTION
Oxygen availability is a critical factor in immune response (1). Each cell in the immune system has
to carry out its functions in an environment marked by a specific level of oxygenation (2). As
immune cells move through tissues, oxygen availability can rapidly change, and these cells thus need
to be able to function in high or low oxygen environments (2).
The discovery of the HIF transcription factor, and the finding that HIF and hypoxic response are
fundamental elements of immune cell function, has led to numerous important findings concerning
the relationships between HIF and immunity (1, 3). These findings have primarily focused on
individual cell types and their responses to hypoxia: studies have, for example, found important
roles for HIF response in the innate immune system, including macrophages, neutrophils, and
dendritic cells, as well as in adaptive immunity in B cells and CD4+ and CD8+ T cells (3–6).org May 2021 | Volume 12 | Article 6335861
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response influences individual cells it becomes important to
understand how these affect cell-cell interactions during
immune response. One key finding in this regard was the
demonstration that hypoxia can trigger myeloid suppression of
T cell proliferation, and that this suppression requires activation
of HIF-1a in myeloid cells (7).
So l id tumors of ten contain immunosuppress ive
microenvironments (8) characterized by cytokines (including
IL10, IL6, galectin-1 and TGF-b) that are upregulated by hypoxia
and HIF signaling (9, 10). PD-L1, a protein that blocks cytotoxic
T cell function, shows increased expression in both tumor cells
and myeloid cells and its expression is in part regulated by HIF-
dependent pathways (10). Loss of myeloid HIF-1a results in
impaired myeloid cell infiltration and inflammation (3, 11, 12)
and decreased tumor progression in a spontaneous mammalian
breast cancer model (7). Loss of myeloid HIF-2a has been linked
to decreased tumor inflammation and progression in murine
models of breast and gastric cancer (13, 14), while tumor-
associated myeloid cells can also contribute to immune
suppression by production of nitric oxide (NO), acting through
the HIF-1a-NOS2 pathway (4, 7).
In this study, we examine the role of deregulated hypoxic
response to determine in detail how key HIF-regulated
myelosuppressive actors influence cytotoxic T cell division, and
how pharmacological manipulation of this pathway might
influence immune response.MATERIAL AND METHODS
Animals
VHLfl/fl LysMCre+, HIF-1afl/fl LysMCre+, HIF-2afl/fl LysMCre+,
Arg-1fl/fl LysMCre+,+, Arg-2fl/fl LysMCre+, Arg-2fl/fl LysMCre+
were generated by crossing transgenic mice homozygous for
loxP-flanked genes of interest (fl/fl) with mice expressing Cre
recombinase driven by the lysozyme M promoter (LysMCre+)
(15). Transgenic mice heterozygous for Cre recombinase and
homozygous for loxP-flanked genes of interest were the
conditional knockouts, and compared to littermates carrying
only the loxP-flanked gene of interest as wild type controls.
Spleens and lymph nodes were harvested from OT-I mice
(003831, The Jackson Laboratory) for isolation of ovalbumin-
specific OT-I CD8+ T cells. All in vivo experiments were
approved by the Swedish ethical approval board (Stockholm
north, N101/16) and were performed on mice aged between 8-16
weeks. Swedish national guidelines were conformed to in all
animal housing and care.
Cell Lines
All tumor cell lines were cultured in DMEM (11995065, Gibco)
supplemented with 10% FBS (10270106, Gibco) and 1%
penicillin/streptomycin (10378016, Gibco).
B16-F10-OVA were generated through co-transfection of the
transposon vector pT2 containing codon-optimized genes for
chicken ovalbumin (OVA; P01012.2), eGFP (ABG78037.1),Frontiers in Immunology | www.frontiersin.org 2neomycin phosphotransferase (NeoR; BAD00047.1) and the
vector encoding transposase SB11.
OVA, eGFP and NeoR were expressed as a polycistronic
peptide interspersed with P2A and furin cleavage sites and
synthesized by Gene Art (Thermo Fisher). This was then
cloned under the promoter SV40 in the transposon vector
pT27BH (gift from Perry Hackett, Addgene plasmid #26556).
Plasmid containg the sleeping beauty transposase (pCMV-SB11,
Addgene plasmid #26552) was a gift from Perry Hackett.
Transfected cells were cultured with 400 mg/mL G418
(10131027, Gibco) three days post transfection in order to select
for transfected cells. Transfection success was confirmed through
flowcytometry analysis of eGFP fluorescence. Clonal B16-F10-
OVA cell line was then produced through limiting dilution.
Antigen Presenting Assay
Bone marrow-derived myeloid cells (BMDM) were generated by
isolation of bone marrow cells from femur and tibia (16), and
cultured for 7 days in DMEM (11995065, Gibco) supplemented
with 10% FBS (10270106, Gibco), 1% penicillin/streptomycin
(10378016, Gibco), 10ng/mL M-CSF and GM-CSF (416-ML-
050/CF and 415-ML-050/CF, R&D Systems). 7 days post
isolation, 100ng/mL LPS (L2630, Sigma-Aldrich) was added to
culture for 24 hours. For the antigen presenting assay, BMDMs
were harvested and incubated with for 1 hour with 100 ng/mL
chicken albumin (OVA) derived peptide (SIINFEKL) (S7951,
Sigma Aldrich), followed by washing three times with PBS
(14190-144, Gibco) and culturing in RPMI (11875085, Gibco)
supplemented with 10% FBS, 1% penicillin/streptomycin and
55mM 2-Mercaptoethanol (21985023, Gibco) in 96 well round
bottom plates (50 000 cells/well). Surface expression of
coactivators and antigen presentation on BMDMs was
confirmed by flow cytometry. CD8+ OT-I T cells were isolated
from gender matched OT-I spleens and lymph nodes by
magnetic bead separation (130-104-075, Miltenyi) and stained
with CellTrace Violet Cell dye (C34557, Invitrogen), for cell
division tracking. The antigen presenting assay was carried out
by adding 200 000 T cells to SIINFEKL-loaded BMDM in a 96
well plate. The co-culture was either preformed at atmospheric
oxygen conditions (21% O2) or at hypoxic conditions (5% or 1%
O2) for three days in a hypoxia workstation (INVIVO2 400,
Ruskinn). Cell division and phenotype was assessed by flow
cytometry. CD8+ OT-I T cells cultured in media with 100 ng/mL
SIINFEKL were used as positive control.
Flow Cytometry
Cell cultures were harvested and stained with Near-IR Dead Cell
Stain Kit (L34975, Thermo Fisher) for dead cell exclusion,
followed by surface staining with fluorochrome labeled
antibodies (Table 1). BD Cytofix/Cytoperm kit (554714, BD
Biosciences) was used for cytoplasmic staining of Granzyme B
and CTLA-4.
NOC-18 Treatment
100 000 CD8+ T cells were activated in 96-well round bottom
plates with CD3/CD28 Dynabeads (11453D, Thermo Fisher) in
200uL RPMI supplemented with 10% FBS, 1% penicillin/May 2021 | Volume 12 | Article 633586
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presence of increasing NOC-18 (ALX-430-014-5005, Enzo)
concentrations (12.5, 25, 100, 200 and 400 mM). For cell
division tracking, cells were loaded with CTV. 72 hours after
activation T cells were analyzed by flow cytometry.
Tumor Assays
Transgenic mice were injected with 2x105 B16-F10-OVA
intravenously by the tail vein. Lungs were perfused with PBS
through the left heart ventricle and collected from euthanized
mice 21 days post injection of tumor cells. The number of
metastatic foci was determined by counting black nodules
macroscopically and sized by scoring system.
Antigen Presenting Assay with FG4592
and DMOG
For optimization, BMDMs were treated with 100, 50, 25, 12.5,
0 mM FG4592 (HIF prolyl-hydroxylase inhibitor) or hypoxia for
24 hours before collected for transcriptional analysis of iNOS
expression using Qiagen RNeasy Kit (cat nr: 74106). cDNA was
produced with iScript cDNA Synthesis Kit (1708890, Bio Rad)
followed by realtime analysis using KiCqStart SYBR GreenFrontiers in Immunology | www.frontiersin.org 3predesigned primers (KSPQ12012, Sigma-Aldrich) for Nos2
(GeneID: 18126) and Hprt (GeneID: 15452). The optimal dose
of FG4592 was selected by choosing the concentration of FG4592
that induces the same level of Nos2 expression as hypoxia. The
antigen presenting assay was performed as described above with
either 12,5 mM FG4592 (15294, Cayman Chemical), 12,5 mM
DMOG (71210 Cayman Chemical) or Dimethyl sulfoxide
(D8418, Sigma-Aldrich) as a solvent control.
Myeloid Suppression Assay
BMDMs and CD8+ T cells were acquired and stained (as
described above) from transgenic and wildtype mice
respectively. CTV stained CD8+ T cells were then activated with
Dynabeads Mouse T-Activator CD3/CD28 (ThermoFisher,
Sweden) for 24 hours. Prior to the co-culture with myeloid cells,
Dynabeads were removed from CD8+ T cell culture by magnetic
separation. Myeloid suppression assay was performed by co-
culture of 50 000 LPS activated BMDM with 200 000 activated
T cells for 72 hours in a round bottom 96 well plate.
Myeloid suppression assays with human primary cells were
performed by isolation of peripheral blood monocytes (PBMC)
using Ficoll-Paque PLUS (17-1440-02, GE Healthcare) fromTABLE 1 | Antibodies and stains used for different analyses performed with flow cytometry.
Stain name Antigen Fluorochrome Dilution Clone





CTLA-4 APC 200 UC10-4F10-
11
GzmB PE 200 GB12
CD44 PE-Cy7 400 IM7
BMDM 1 Live/dead APC-Cy7 500
Fc block 50 93
CD80 Pacific Blue 200 16-10A1
CD86 Alexa Fluor 488 200 GL-1
H2KB-OVA PE 200 25-D1.16
CD11c PE-Cy7 125 HL3
H2KB Alexa Fluor 647 200 AF6-88.5
BMDM 2 Live/dead APC-Cy7 500
Fc block 50 93
PD-L1 PE 100 MIH5
CD11c PE-Cy7 125 HL3
MHC Class
II
Alexa Fluor 647 1600 M5/114.15.2
Human Monocyte Live/dead APC-Cy7 500
Fc block 50
CD16 Horizon V450 200 3G8
CD45 FITC 200 HI30
CD11b PE 200 M1/70
CD25 Alexa Fluor 647 200 M-A251
Human Ex Vivo Lymphoid CTV eFluor 450
Live/dead APC-Cy7 500
Fc block 50
CD8 BV510 200 SK1
CD45RA APC 100 HI100
TCR a/b PerCP/Cy5.5 200 IP26
CD45RO FITC 100 UCHL1
GzmB PE 200 GB12May 2021 | Volume 12 | AViability staining was performed using or Near-IR Dead Cell Stain Kit (L34975, Thermo Fisher).rticle 633586
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(Stockholm, Sweden). CD8+ T cells and monocytes were
isolated by microbead separation using positive selection for
CD8+ T cells (130-045-201, Miltenyi) followed by negative
selection for pan-monocytes (130-096-537, Miltenyi). Prior to
co-culture of monocytes and CD8+ T cells, 100 ng/mL LPS was
added to the monocyte culture, while CD8+ T cells were activated
using plate bound Ultra-LEAF Purified anti-human CD3
antibody (clone OKT3, Biolegend). 24 hours post activation
monocytes and CD8+ T cells were washed once with complete
RPMI cell media and co-cultured for 72 hours in a round bottom
96 well plate (50 000 monocytes and 200 000 CD8+ T cells per
well), followed by analysis with flow cytometry. As positive
controls activated CD8+ T cells were cultured with plate bound
anti-human CD3 antibody with similar treatments and
conditions as co-cultured samples. All cell cultures were
performed in RPMI supplemented with 10% FBS, 1%
penicillin/streptomycin and 55mM 2-Mercaptoethanol.RESULTS
In order to better understand oxygen-mediated changes in
myeloid/lymphoid interactions, we first sought to determine
whether increased expression of HIF transcription factors in
myeloid cells can drive immunosuppression during antigen-
dependent CD8+ T cell activation. We utilized a co-culture
system in which myeloid cells present a specific antigen (the
ovalbumin-derived OVA peptide) to transgenic CD8+ T cells
bearing the OT-I T cell receptor specific for that peptide (OT-I
T cells).
We undertook co-culture of bone marrow-derived myeloid
cells (BMDMs) which were LPS-activated and loaded with the
OVA peptide SIINFEKL. The myeloid cells present antigen
through H-2Kb to naïve CD8+ T cells from transgenic mice
expressing the OT-1 transgene, specific for the SIINFEKL
peptide (this experimental model is outlined in Supplementary
Figures 1A–C). As a positive control, OT-I CD8+ T cells were
cultured with SIINFEKL peptide, but without BMDMs. As
shown in representative histograms (Supplementary Figure
1D), there were no significant oxygen-dependent effects seen
on CD8+ T cell division or activation (Supplementary Figure
1D) detected after three days in this experimental assay.
Previous work from our group has found that T cell
proliferation following TCR triggering is suppressed in hypoxia
during co-culture with wild type myeloid cells, and found this
suppression to be dependent on an intact myeloid cell HIF-1a
gene (7). To further examine this, the genetic components of
hypoxia-driven suppression of CD8+ T cell division by myeloid
cells were determined. As shown in Figure 1A, loss of HIF-1a in
myeloid cells increased cell division in co-cultured CD8+ OT-I
expressing T cells under both high and low oxygen conditions
following activation by antigen presenting myeloid cells.
Conversely, loss of HIF-2a (Figure 1A) in myeloid cells had
no significant effect on co-cultured antigen activated T cells
during either high or low oxygen culture. This indicates that inFrontiers in Immunology | www.frontiersin.org 4this experimental system, the key transcriptional effector of
myeloid immunosuppression caused by hypoxia is HIF-1a.
We next examined a number of HIF target genes that
regulate nitric oxide that are known to induce myeloid
immunosuppression of T cell responses (4); these genes can
either act to suppress nitric oxide production (Arg1 and Arg2) or
induce it (NOS2). Arg1 and Arg2 have been shown to be HIF-2a
target genes in myeloid cells, whereas NOS2 is primarily
regulated by HIF-1a in these cells (4, 17). Arg1 deletion in
myeloid cells (using Arg1fl/fl and Arg1fl/fl LysMCre+strain mice)
results in an insignificant increase in T cell division in high
oxygen, with little significant change in division in low oxygen
(Figure 1A). However, Arg2 deletion (using Arg2fl/fl and Arg2fl/fl
LysMCre+strain mice) has little effect on T cell division in co-
culture (Figure 1A). This is consistent with the lower levels of
Arg2 expression seen in myeloid cells relative to Arg1 expression.
Interestingly, loss of myeloid cell NOS2 (using NOS2fl/fl and
NOS2fl/fl LysMCre+strain mice) allows increased T cell antigen
presentation-induced division in both high and low oxygen
conditions relative to co-culture with wild type myeloid cells
(Figure 1A).
Loss of myeloid cell HIF-1a caused a post-activation increase
in expression of the activation marker Granzyme B on CD8+ T
cells during high oxygen co-culture; whereas loss of NOS2 in
myeloid cells increased Granzyme B expression under both low
and high oxygen co-culture conditions (Figure 1B). As can be
seen in Figure 1C, increasing concentrations of an NO donor
molecule, NOC-18, effectively suppresses division of activated T
cells; this occurs in a dose-dependent manner.
As myeloid cells are known to have an important impact on
establishment of metastatic tumors (18), mice with a loss of
function of the NOS2 gene in myeloid cells (using NOS2fl/fl and
NOS2fl/fl LysMCre+strain mice) were injected intravenously with
OVA expressing B16-F10 cells, a metastatic melanoma cell line.
As shown here, mice lacking myeloid NOS2 had decreased
numbers of metastatic foci (Figure 1D). This indicates that in
this model, myeloid NOS2 expression acts to facilitate metastatic
tumor initiation, and may affect overall growth of these tumors,
although there was no significant effect of this mutation on
metastatic tumor size in these experiments.
To determine whether increased amounts of HIF expression
from myeloid cells inhibits T cell division under high oxygen co-
culture, we employed the antigen presentation conditions
described above with CD8+ T cells and myeloid cells with a
null mutation in the VHL gene (using VHLfl/fl and VHLfl/fl
LysMCre+strain mice). These mutant mice have increased levels
of HIF expression under high oxygen conditions due to
diminished oxygen-mediated HIFa degradation. As can be
seen in Figure 2A, while wild type myeloid cells suppress T
cell division after activation in an oxygen-dependent manner
during co-culture, VHL mutant myeloid cells completely
suppress T cell division, even under high oxygen conditions.
A number of inhibitors of the prolyl hydroxylase enzymes are
currently either in clinical use or under evaluation, primarily for
the treatment of anemia (19). These inhibitors act to block
hydroxylation of two of the proline residues in the HIF-alphaMay 2021 | Volume 12 | Article 633586
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degradation by VHL complexes. As a functional read-out of this
effect, we show in Figure 2B that stabilization of HIF by the
prolyl hydroxylase inhibitor FG4592 (20, 21) gives rise to a dose-Frontiers in Immunology | www.frontiersin.org 5dependent increase in HIF-dependent NOS2 mRNA
transcription in primary myeloid cells. In Figure 2B we also
show that activated CD8+ T cells cultured alone or treated with
12.5 micromolar levels of the prolyl hydroxylase inhibitorA
B
DC
FIGURE 1 | Myeloid HIF-1a inhibits antigen induced CD8+ T-cell division through NOS2. (A) Antigen presenting assay showing representative CTV histograms and
division fraction of CD8+ T-Cells co-cultured with HIF-1a fl/fl (WT) and HIF-1a fl/fl LysMCre+ (HIF-1a KO), HIF-2a fl/fl (WT) and HIF-2a fl/fl LysMCre+ (HIF-2a KO), Arg-1fl/fl
(WT) and Arg-1fl/fl LysMCre+ (Arg-1 KO), Arg-2fl/fl (WT) and Arg-2fl/fl LysMCre+ (Arg-2 KO), NOS2fl/fl (WT) and NOS2fl/fl LysMCre+ (NOS2 KO) BMDMs in 21% or 1%
oxygen. (B) Expression of Granzyme B as representative histograms and normalized MFI of CD8+ T-Cells activated by antigen presenting HIF-1a fl/fl vs HIF-1a fl/fl
LysMCre+ and NOS2fl/fl vs NOS2fl/fl LysMCre+ BMDMs in 21% or 1% oxygen. (C) CD8+ T-cells activated for 72 hours in 5% O2 and cultured for 2 days with increasing
concentration of nitric oxide donor (NO) NOC-18. n=3 donors (D) 10-13 week old mice were injected intra venously with 0.2x106 B16-F10-OVA tumor cells. The
mice were sacrificed 21 days post injection for collection of lungs. Number of foci and size score NOS2fl/fl vs NOS2fl/fl LysMCre+ mice. Data presented as scatter dot
plots or violin plots, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Statistical analysis was performed with unpaired T test, n= 3-4 bone
marrow donors (A, B) and n= 11-15 mice per group (D).May 2021 | Volume 12 | Article 633586




FIGURE 2 | Genetically and compound induced myeloid hypoxia blocks CD8+ T-cell division in vitro. (A) Representative flow cytometry histograms of CTV stained
CD8+ T-cells co-cultured with OVA presenting BMDMs in 21%, 5%, 1% oxygen and with BMDMs without Von Hippel-Lindau (VHLfl/fl LysMCre+) in 21% oxygen,
division fraction of CD8+ T-cells co-cultured with antigen presenting wildtype BMDMs in different oxygen levels and division fraction of CD8+ T-cells co-cultured with
VHLfl/fl (WT) vs VHLfl/fl LysMCre+ (VHL KO) BMDMs in 21% oxygen. (B) NOS2 mRNA expression in BMDMs cultured with increasing concentration of FG-4592 (HIF
prolyl-hydroxylase inhibitor) or hypoxia (with ranging values demonstrated as blue shade on y axis) and CD8+ T-cells in a single culture with DMSO or 12.5 µM FG-
4592. (C) Antigen presenting assay; BMDM and CD8+ T-cell co-culture treated either with FG-4592 compared to DMSO controls and expression of Granzyme B in
CD8+ T-cells in co-culture with BMDMs. (D) Antigen presentation assay performed with NOS2fl/fl or NOS2fl/fl LysMCre+ BMDMs in 21% treated with 12.5 µM FG-
4592 or DMOG and co-culture of pre-activated BMDM from NOS2fl/fl or NOS2fl/fl LysMCre+ mice and pre-activated CD8+ T-cells from wildtype mice. Co-cultures
were performed in media containing DMSO, 12.5 µM FG-4592 or DMOG. Data presented as scatter dot plots, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001,
*****P < 0.00001; ns, not significant. Statistical analysis was performed with unpaired T test, n= 4-8 bone marrow donors/group.Frontiers in Immunology | www.frontiersin.org May 2021 | Volume 12 | Article 6335866
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FIGURE 3 | Human monocyte compound induced HIF response blocks human T-cell division in vitro. (A) Illustration of the experimental layout. Human monocytes
and CD8+ T-cells were isolated from peripheral blood mononuclear cells and activated with 100 ng/mL LPS and plate bound anti-CD3 antibodies (respectively) for
24 hours. Activation was followed by culturing activated CD8+ T-cells alone or co-culturing CD8+ T-cells with either unstimulated or LPS stimulated monocytes.
(B) Percentage divided CD8+ T-Cells after three days in three different culturing conditions and treatments; DMSO, 1% O2 or 12.5 µM. All samples presented as the
difference to untreated single cultured donor-matched CD8+ T-cells. (C) Expression of Granzyme B in CD8+ T-cells treated as in (B). Data is log2 fold change MFI
relative to untreated single cultured donor-matched CD8+ T-cells. Data presented as violin plots or representative histograms, *P < 0.05, **P < 0.01, ***P < 0.001;
ns, not significant. Statistical analysis was performed with Two-way RM ANOVA and Tukey’s multiple comparisons test, n = 6 blood donors/group.Frontiers in Immunology | www.frontiersin.org May 2021 | Volume 12 | Article 6335867
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Figure 2C, in a co-culture system, the prolyl hydroxylase
inhibitor has a strongly inhibitory effect on T cell division.
This extends to inhibition of the expression of a number of
markers of T cell activation, including Granzyme B, and CTLA4
(Figure 2C).
In order to ascertain whether this myeloid suppression of
CD8+ T cell division is NO-dependent, we performed the antigen
presenting co-culture assay described above with NOS2 deleted
myeloid cells, in combination with one or the other of the prolyl
hydroxylase inhibitors FG4592 and DMOG (Figure 2D) (21, 22)
We have previously shown that the NOS2 gene is the
predominant source for NO in activated murine myeloid cells
(4, 7). As shown in Figure 2D, suppression of myeloid NO
production via deletion of the myeloid NOS2 gene significantly
reduced the myelosuppression caused by these two prolyl
hydroxylase inhibitors in co-culture (Figure 2D). This
indicates that a key aspect of the myelosuppression caused by
pharmacological activation of HIF is NO production by
myeloid cells.
As these experiments were all carried out in murine systems,
in order to investigate whether these findings are relevant to
human cells, we carried out a myeloid suppression assay using
human donor peripheral blood monocyte-derived monocytes
stimulated ex vivo with LPS (Supplementary Figure 2A) and
CD8+ T cells (Supplementary Figure 2B), either in hypoxia, or
with FG4592 (Figure 3A). We found that, as with murine CD8+
T cells, FG4592 does not alter CD8+ T cell division in a
monoculture of cytotoxic T cells; however, in co-culture with
monocytes, FG4592 causes significant suppression of CD8+ T
cell division (Figure 3B). Co-cultures of LPS-stimulated
monocytes and CD8+ T cells with FG4592 showed suppression
of CD8+ T cell expression of the T cell effector molecules
Granzyme B (Figure 3C) and CD45RO (Supplementary
Figure 2C), while leaving expression of the marker CD45RA
unaffected (Supplementary Figure 2D). Overall, this data
confirms that FG4592 enhances myeloid cell suppression of
CD8+ T cell division and activation in both murine and
human primary cell cultures.DISCUSSION
We show here that even intermediate levels of hypoxia can act to
trigger myelosuppressive properties in co-culture of myeloid cells
with CD8+ T cells. Follow up experiments demonstrated that
myeloid inhibition of T cell proliferation was dependent on NO
production, specifically through the action of the HIF-1a
transcription factor. LPS-stimulated myeloid cells will produce
significant amounts of NO even in 21% O2 (23), however,
lowering oxygen levels increases nitric oxide production and
therefore increases myelosuppression, explaining the observation
that even at high oxygen levels, deletion of myeloid HIF-1a or
NOS2 allows increased T cell activation and expansion.
Activation of cytotoxic T cells in the presence of the nitric
oxide donor NOC-18 suggests that inhibition by NO is dose
dependent, reinforcing the hypothesis that the effect of the highlyFrontiers in Immunology | www.frontiersin.org 8labile NO molecule is strongest when myeloid cells and T cells
are in close proximity to one another, such as when an
immunological synapse is formed. The reduced numbers of
metastases seen here in mice lacking myeloid NOS2 suggest
that myeloid NO may contribute to early stages of tumor
establishment, particularly as the size of metastatic lesions was
not significantly different between wild type and NOS2
mutant mice.
Genetic and pharmacological induction of myeloid HIF-1a
(either through deletion of VHL or treatment with FG4592)
demonstrated a strong connection between HIF-1a-driven NO
production and the ability of myeloid cells to suppress cytotoxic
T cell division and activation. As shown in Figure 2D, this
myeloid suppression is independent of whether T cells are
activated independently first, or activated directly in the
presence of myeloid cells.
It should be noted that there is extensive evidence for
interaction of the NF-kB pathway and HIF and hypoxia (24).
An important element for future investigation of the
mechanisms of hydroxylase inhibition and the interaction
between the innate and adaptive immune system will
necessarily need to take this into account. Future studies
should help to determine more exactly when hypoxia and HIF
activation effect T cell proliferation following antigen
presentation and recognition. The timing of these events
relative to oxygenation flux will likely be in part dependent on
when NF-kB function is itself triggered or suppressed.
Inhibition of PHD activity has been shown to have a potent
therapeutic value in models of inflammatory diseases such as
colitis (25). Studies have also shown that genetic deletion of
PHD-1 in murine models of dextran sulfate sodium (DSS)
-induced colitis protected against disease (26). Furthermore,
various pharmacological compounds that influence the HIF
pathway have demonstrated a protective role in murine models
of colitis, and in suppression of disease associated inflammation
(27–30). Thus, one possible interpretation of our data is that
some of these findings cited above of an anti-inflammatory role
for HIF may be due to a HIF-regulated myeloid cell suppression
of T cell-induced or -dependent tissue damage.
FG4592 has recently been approved for treatment of
anemia in patients suffering from chronic kidney diseases (31).
Our data present an interesting and potentially important
concern regarding the effects of this and similar drugs on the
immune system, and in particular their potential role in
modulating myelosuppression.DATA AVAILABILITY STATEMENT
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633586/full#supplementary-materialFrontiers in Immunology | www.frontiersin.org 9Supplementary Figure 1 | The antigen presenting assay. (A) Illustration of the in
vitro antigen presenting assay. Bone marrow derived myeloid cells (BMDM) were
activated with 100 ng/mL LPS for one day, followed by 1-hour incubation with 100
ng/mL OVA; 257-264 (SIINFEKL). CellTrace Violet Staining (CTV) stained CD8+ OT-I
T-Cells were co-cultured with BMDMs for 3 days. (B) Representative gating
strategy used to analyze BMDMs surface markers, and co-activators and antigen
presenting surface proteins were upregulated in BMDMs stimulated with LPS.
(C) Gating strategy to measure OT-I T-Cell division and surface markers.
Expression level of surface markers was determined on the whole live CD8+
population whereas division level was defined by fraction of divided live CD8+
T-cells. (D) Representative CTV plots of negative and positive controls for antigen
presenting assays with division fraction of untreated CD8+ T-cells (negative control)
or activated by directly adding 100 ng/mL SIINFEKL to culturing media (positive
control) without any presence of bone marrow derived myeloid cells. Bottom row
shows representative histograms and normalized median florescence intensity (MFI)
of Granzyme B and CD44 expression in activated CD8+ T-cells, cultured in 21%,
5% and 1% O2. MFI values were normalized to 21% oxygen. Data presented as
scatter dot plots, *P< 0.05, **P< 0.01, ***P<0.001, ****P< 0.0001; ns, not
significant. Statistical analysis was performed with unpaired T test, n = 8 bone
marrow donors/group or 6-3 CD8+ OT-I T-Cell donors/group.
Supplementary Figure 2 | Human monocyte compound induced hypoxia alters
expression of human CD8+ T-cell activation markers. (A) Representative gating
strategy used to analyze monocyte surface markers followed by scatter dot plots
and representative histograms of CD25 and CD16 surface expression of
monocytes with or without LPS treatments. Statistical analysis was performed with
(donor) paired T-test. (B) Representative gating strategy used to analyze CD8+
T-cell division and expression of different surface markers. (C) Expression of
CD45RO and (D) CD45RA as log2fold change in CD8+ T-cells from different
conditions and treatments. Data presented as violin plots or representative
histograms, *P< 0.05, **P< 0.01, ***P<0.001; ns, not significant. Statistical analysis
was performed with Two-way RM ANOVA and Tukey’s multiple comparisons test,
n = 6 blood donors/group. All samples were standardized to untreated single
cultured donor matched CD8+ T-cells.REFERENCES
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